A2A adenosine receptor protects tumors from antitumor T cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2006-08-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.0605251103PMID 16916931PMCID PMC1559765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse.

  2005cited by this paper
• Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer

  2005cited by this paper
• Cancer immunotherapy: breaking the barriers to harvest the crop

  2004cited by this paper
• Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors.

  2004cited by this paper
• Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin.

  2003cited by this paper
• Angiogenesis and apoptosis.

  2003cited by this paper
• Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo.

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Hypoxia — a key regulatory factor in tumour growth

  2002cited by this paper
• T cells take aim at cancer

  2002cited by this paper
• Molecular mechanisms for protein kinase A-mediated modulation of immune function.

  2002cited by this paper
• Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.

  2002cited by this paper
• Adenosine acts through an A3 receptor to prevent the induction of murine anti‐CD3‐activated killer T cells

  2002cited by this paper
• Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity1

  2001cited by this paper
• Regression of Extensive Pulmonary Metastases in Mice by Adoptive Transfer of Antigen-Specific CD8+ CTL Reactive Against Tumor Cells Expressing a Naturally Occurring Rejection Epitope

  2001cited by this paper
• IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

  2001cited by this paper
• Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection.

  2001cited by this paper
• Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

  2001cited by this paper
• Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses

  2001cited by this paper
• Immunity against solid tumors?

  2001cited by this paper
• Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice.

  2001cited by this paper
• Role of the extracellular cAMP-adenosine pathway in renal physiology.

  2001cited by this paper
• Progress in the development of immunotherapy for the treatment of patients with cancer

  2001cited by this paper
• International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

  2001cited by this paper
• Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin

  2000cited by this paper
• Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

  2000cited by this paper
• Study of A2A adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A2A receptor‐unrelated lymphotoxicity

  2000cited by this paper
• CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

  2000cited by this paper
• Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.

  1999cited by this paper
• Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

  1999cited by this paper
• Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors.

  1999cited by this paper
• Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.

  1998cited by this paper
• Role of A2a Extracellular Adenosine Receptor-Mediated Signaling in Adenosine-Mediated Inhibition of T-Cell Activation and Expansion

  1997cited by this paper
• The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine.

  1997cited by this paper
• Memory of Extracellular Adenosine A2A Purinergic Receptor-mediated Signaling in Murine T Cells*

  1997cited by this paper
• Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release.

  1997cited by this paper
• Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.

  1997cited by this paper
• Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape

  1996cited by this paper
• Adenosine receptor ligands: differences with acute versus chronic treatment.

  1996cited by this paper
• Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine.

  1995cited by this paper
• Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.

  1994cited by this paper
• Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice

  1994cited by this paper
• Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen

  1989cited by this paper
• Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene

  1988cited by this paper
• Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway.

  1988cited by this paper
• In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs

  1968cited by this paper

• Tumor cell death by ferroptosis contributes to an immunosuppressive tumor microenvironment in syngeneic murine models of cancer

  2026cites this paper
• Bridging the Translational Gap in HNSCC Immunotherapy: From Resistance Mechanisms to High-Fidelity Preclinical Models.

  2026cites this paper
• Potential Gastric Cancer Biomarker in Gastric Juice: Adenosine and Its Role in the Immune Evasion Mechanism of Gastric Cancer

  2026cites this paper
• Targeting CD73 and correcting adenosinergic signaling in critically ill patients

  2026cites this paper
• Metabolic causal factor of immune cell function and fate in the tumor microenvironment.

  2026cites this paper
• CAR Intrinsic Design Pre-Shapes Transcriptional and Metabolic Networks in CAR T Cells

  2026cites this paper
• Pharmacokinetics-Driven Optimization of Immunotherapeutic Agents Targeting the Adenosine A2A Receptor (A2AR) and Histone Deacetylases (HDACs).

  2026cites this paper
• From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma

  2026cites this paper
• Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis.

  2026cites this paper
• Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation

  2026influential citation
• T‐Cell Immunity and Lung Cancer

  2026cites this paper
• Inhibition of A2AR alleviates adenosine-mediated suppression of plasma cell differentiation

  2025cites this paper
• Metabolic regulation of immunity in the tumor microenvironment.

  2025cites this paper
• CD39 and CD73: biological functions, diseases and therapy

  2025cites this paper
• Cytolytic γδ T-cells and IFNγ-producing CD4-lymphocytes characterise the early response to MTBVAC tuberculosis vaccine

  2025cites this paper
• Chirality-Guided Optimization of A2A Adenosine Receptor Antagonists for Enhanced Metabolic Stability and Antitumor Efficacy.

  2025cites this paper
• Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia–induced immunosuppression

  2025cites this paper
• Discovery of Novel Triple A1/A2A/A2B Adenosine Receptor Antagonists for Cancer Immunotherapy.

  2025cites this paper
• Adenosine receptor subtype modulators: Insight into molecular mechanisms and their therapeutic application.

  2025cites this paper
• Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices

  2025cites this paper
• Adaptation of Natural Killer Cells to Hypoxia: A Review of the Transcriptional, Translational, and Metabolic Processes

  2025cites this paper
• Synergistic blockade of SHP-2 and A2AR signal pathways with targeted nanoparticles restores anti-tumor immunity of CD8+ T cells.

  2025cites this paper
• Combining magnetic hyperthermia and ectonucleotidase inhibition to amplify antitumor immunity

  2025cites this paper
• Therapeutic potential of adenosine receptor modulators in cancer treatment

  2025cites this paper
• Tumor-derived vesicles in immune modulation: focus on signaling pathways

  2025cites this paper
• Insights from Clinical Trials on A2A Adenosine Receptor Antagonists for Cancer Treatment.

  2025cites this paper
• Overcoming multifaceted challenges in cancer treatment: Targeting signal transduction pathways and tumor microenvironment for enhanced therapeutic efficacy

  2025cites this paper
• Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implications

  2025cites this paper
• Discovery of a novel CD39 inhibitor by DNA-Encoded library screening.

  2025cites this paper
• Advances in integrating biomaterials with CAR-T cells for enhancing solid tumor therapy.

  2025cites this paper
• Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells

  2025cites this paper
• Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer

  2025cites this paper
• Metabolic control of feto–placental development and pregnancy outcomes

  2025cites this paper
• Engineered natural killer cells for cancer therapy.

  2025cites this paper
• Treatment strategies for leptomeningeal disease in patients with breast cancer.

  2025cites this paper
• Purinergic signaling in ovarian carcinoma

  2025cites this paper
• Targeting Metabolic Reprogramming in Tumor: From Mechanisms to Precision Immunotherapies

  2025cites this paper
• Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors

  2025influential citation
• Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy.

  2025cites this paper
• Prostaglandin E2-EP2/EP4 signaling induces the tumor-infiltrating Treg phenotype for tumor growth

  2025cites this paper
• Know Your ABCs: Discovery, Differentiation, and Targeting of T‐Bet+ B Cells

  2025cites this paper
• Tumor Metastasis: Mechanistic Insights and Therapeutic Intervention

  2025cites this paper
• Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations

  2025cites this paper
• Microbiota‐Derived Inosine Suppresses Systemic Autoimmunity via Restriction of B Cell Differentiation and Migration

  2025cites this paper
• Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer

  2025cites this paper
• Adenosine Kinase: An Epigenetic Modulator and Drug Target

  2025cites this paper
• Tumor‐Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion

  2025cites this paper
• Metabolites as agents and targets for cancer immunotherapy

  2025cites this paper
• Structural Simplification from Tricyclic to Bicyclic Scaffolds: A Long-Term Investigation in the Field of Adenosine Receptor Antagonists

  2025cites this paper
• Targeting tumor microenvironmental barriers to enhance immunogenic cell death in solid tumors

  2025cites this paper
• Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma.

  2025cites this paper
• Relative adenosine production assay suitable for 2D and 3D tumor cell culture.

  2025cites this paper
• Bioactive polydopamine nanomedicines-assisted cancer immunotherapy

  2025cites this paper
• CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients

  2025cites this paper
• Tumor immune evasion: Systemic immunosuppressive networks beyond the local microenvironment

  2025cites this paper
• The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities

  2025cites this paper
• Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors

  2025cites this paper
• Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation.

  2025cites this paper
• Regio- and Stereoselective Ribose Modification in Truncated 2,8-Disubstituted Adenosine Scaffold to Develop Highly Potent A2A Adenosine Receptor Antagonists.

  2025cites this paper
• Gas-mediated reinforcement of cancer therapies: emerging strategies and future perspectives

  2025cites this paper
• Chronic heat stress induces hepatic injury, alters hematological parameters, thermotolerance response in gilts through liver multi-omics analysis.

  2025cites this paper
• Potential of Adora2b as an immunotherapeutic target for gastric cancer

  2025cites this paper
• Gut microbial metabolites in cancer immunomodulation

  2025cites this paper
• Caffeine as a Modulator in Oncology: Mechanisms of Action and Potential for Adjuvant Therapy

  2025cites this paper
• Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer

  2025cites this paper
• Mechanisms of Sepsis from a Metabolic Immunology Perspective: A Bidirectional Mendelian Randomization and Single-Cell Sequencing Study of CD39+ Cells.

  2025cites this paper
• Rationally Engineered Adenosine A2A Decoy Receptor for Reversing Immunosuppression of Breast Cancer.

  2025cites this paper
• The glioma microenvironment and its impact on antitumor immunity

  2025cites this paper
• Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced T cell-mediated tumor immunotherapy

  2025cites this paper
• Targeting the adenosinergic axis in cancer immunotherapy: Insights into A2A and A2B receptors and novel clinical combination strategies.

  2025cites this paper
• Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment

  2025cites this paper
• Nanoliposome loaded with 5-fluorouracil and Dorema aucheri extract reduces tumor growth in a mouse model of colorectal cancer

  2025cites this paper
• Structural Insights into Partial Activation of the Prototypic G Protein-Coupled Adenosine A2A Receptor.

  2024cites this paper
• Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer

  2024cites this paper
• Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?

  2024cites this paper
• GRHL2 suppression of NT5E/CD73 in breast cancer cells modulates CD73-mediated adenosine production and T cell recruitment

  2024cites this paper
• The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.

  2024cites this paper
• Cancer cell metabolism and antitumour immunity

  2024cites this paper
• Immune Cell Migration to Cancer

  2024cites this paper
• CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors.

  2024cites this paper
• Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy.

  2024cites this paper
• Reprogramming of tumor-associated macrophages by metabolites generated from tumor microenvironment

  2024cites this paper
• Adenosine and Cortical Plasticity

  2024cites this paper
• Erythrocyte‐Derived Bioactive Nanovesicles Reverse the Immunosuppressive Function of Adenosine for Tumor Photoimmunotherapy

  2024cites this paper
• Cutaneous melanoma and purinergic modulation by phenolic compounds

  2024cites this paper
• Mechano-sensitivity of β2-adrenoceptors enhances constitutive activation of cAMP generation that is inhibited by inverse agonists

  2024cites this paper
• Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model

  2024cites this paper
• Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine

  2024cites this paper
• Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer

  2024cites this paper
• Purinergic pathways and their clinical use in the treatment of acute myeloid leukemia

  2024cites this paper
• Oxygen carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced suppression and improve cancer immunotherapy

  2024cites this paper
• Purinergic enzymes on extracellular vesicles: immune modulation on the go

  2024cites this paper
• Metabolic engineering for optimized CAR-T cell therapy

  2024cites this paper
• CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4

  2024cites this paper
• Suppressing the Hypoxia‐Adenosinergic Axis by a Tailored Nanoreactor for Enhanced Photothermal Immunotherapy

  2024cites this paper
• Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma

  2024cites this paper
• HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.

  2024cites this paper
• Intercellular crosstalk shapes purinergic metabolism and signaling in cancer cells.

  2024cites this paper
• Development of a Sensitive Anti-Mouse CD39 Monoclonal Antibody (C39Mab-1) for Flow Cytometry and Western Blot Analyses

  2024cites this paper
• Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor

  2024cites this paper